Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Short Interest Update

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) was the recipient of a large growth in short interest in January. As of January 31st, there was short interest totalling 631,300 shares, a growth of 437.3% from the January 15th total of 117,500 shares. Currently, 3.6% of the company’s shares are short sold. Based on an average daily volume of 3,650,000 shares, the days-to-cover ratio is currently 0.2 days.

Virpax Pharmaceuticals Stock Performance

NASDAQ VRPX opened at $0.27 on Thursday. Virpax Pharmaceuticals has a 1 year low of $0.23 and a 1 year high of $5.48. The stock’s 50-day moving average price is $0.33 and its two-hundred day moving average price is $0.60.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Virpax Pharmaceuticals stock. Garden State Investment Advisory Services LLC acquired a new position in Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) in the third quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 57,300 shares of the company’s stock, valued at approximately $40,000. Garden State Investment Advisory Services LLC owned 1.17% of Virpax Pharmaceuticals as of its most recent filing with the SEC. Hedge funds and other institutional investors own 32.23% of the company’s stock.

Virpax Pharmaceuticals Company Profile

Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.